Lupus & antiphospholipid syndrome
Neutralizing autoantibodies against interferon alpha in systemic lupus erythematosus: Prevalence, age of onset, and clinical associations
Authors' conclusion
Approximately 5% of SLE patients have neutralizing anti-IFN antibodies, which may present early in disease or develop later in life.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients from the Lund Lupus Cohort
- Participants
- 173 patients
- Exposure
- Patients with neutralizing anti-IFN antibodies vs antibody-negative patients
- Neutralizing anti-IFN abn = 9
- Outcome
- Prevalence of anti-IFN ab
Methodological detailslongitudinal sample analysis
- Longitudinal sample analysis
Main finding
As reported in the abstract
Positive for anti-IFN ab by ELISA
Eighteen (10.4%)
Anti-IFN ab with interferons (IFN) neutralizing capacity
nine patients (5.2%)
Observational data: associations, not effects.
Further findings
Demography, organ damage or ACR classification criteria, neutralizing ab vs antibody-negative
- No statistically significant differences
Age, neutralizing ab vs antibody-negative
- Slightly older with neutralizing ab (median age)
- 59 vs 45 years, p = .14
Renal involvement, neutralizing ab vs antibody-negative
- Higher proportion with neutralizing ab
- 67% vs 33%, p = .088
Age of onset of neutralizing anti-IFN ab (longitudinal)
- Late-onset (≥65 years)
- n = 4
- Early-onset (≤40 years)
- n = 5
- One late-onset patient positive at diagnosis at age 69; early-onset ab at or soon after diagnosis in four cases
Organ damage, with vs without neutralizing ab
- Did not differ
- P = 0.65
Free of organ damage at latest follow-up · 2-38 years after anti-IFN ab detection
- Patients with neutralizing ab free of organ damage
- three of nine
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →